Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: NeuGene antisense compounds - Sarepta Therapeutics

Drug Profile

Research programme: NeuGene antisense compounds - Sarepta Therapeutics

Alternative Names: AVI 4179; AVI 4451; AVI 4XXX; NeuBiotics

Latest Information Update: 18 Apr 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines
  • Mechanism of Action Genetic transcription inhibitors; HMG-CoA reductase inhibitors; Intercellular adhesion molecule 1 antagonists; Intercellular adhesion molecule 3 antagonists; NF-kappa B inhibitors; Nitric oxide synthase inhibitors; Proto-oncogene protein c-myc modulators; RNA interference; RNA synthesis inhibitors; Testosterone congener inhibitors; Transforming growth factor beta stimulants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax; Bacterial infections; Ricin poisoning
  • Discontinued Coronary artery restenosis; Hypercholesterolaemia; Immunological disorders; Inflammation; Multiple sclerosis; Prostate cancer; Stem cell mobilisation

Most Recent Events

  • 18 Apr 2013 No development reported - Preclinical for Anthrax in USA (Parenteral)
  • 18 Apr 2013 No development reported - Preclinical for Bacterial infections in USA (Parenteral)
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top